Russell Frank Company’s Adamas Pharmaceuticals ADMS Stock Holding History

Russell Frank Company’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-83,773	Closed	-$2.4M	–	3071
2015 Q4	$2.4M	Buy	83,773 +45,652	+120%	+$769K	﹤0.01%	1725
2015 Q3	$638K	Sell	38,121 -52,821	-58%	-$1.2M	﹤0.01%	2398
2015 Q2	$2.38M	Buy	90,942 +59,449	+189%	+$1.16M	﹤0.01%	1871
2015 Q1	$551K	Buy	31,493 +18,055	+134%	+$309K	﹤0.01%	2379
2014 Q4	$232K	Buy	+13,438	New	+$204K	﹤0.01%	2593

Other funds holding ADMS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

CPH

C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Russell Frank Company's ADMS Position: Q1 2016 in Review

Russell Frank Company sold out of Adamas Pharmaceuticals (ADMS) in Q1 2016, closing a stake of 83,773 shares — an estimated $2.4M sold.

Russell Frank Company first reported a position in ADMS in Q4 2014 and held it in 5 quarters. The position peaked at $2.4M in Q4 2015. 84 funds tracked by Wall St. Rank hold ADMS as of Q1 2016.

Russell Frank Company reported no remaining Adamas Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 83,773 Adamas Pharmaceuticals shares in Q1 2016, an estimated $2.4M.
Russell Frank Company first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Russell Frank Company's Adamas Pharmaceuticals position peaked at $2.4M in Q4 2015.
84 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.